Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | TACR2 | P21452 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956912 | 0.86 | ERN1 (0.47) | ERN1ALDH1A1HPGDSMN1; SMN2PDK2 | |
| SCHEMBL12813483 | 0.86 | ERN1 (0.47) | ERN1ALDH1A1HPGDSMN1; SMN2PDK2 | |
| SCHEMBL29951662 | 0.83 | MLYCD (0.47) | ERN1ALDH1A1HPGDSMN1; SMN2CES2 | |
| SCHEMBL16599656 | 0.83 | MLYCD (0.47) | ERN1ALDH1A1HPGDSMN1; SMN2CES2 | |
| SCHEMBL29956989 | 0.81 | HSP90AA1 (0.51) | ALDH1A1HPGDSMN1; SMN2PDK2KCNH2 | |
| SCHEMBL2653855 | 0.81 | CES2 (0.59) | ERN1ALDH1A1HPGDSMN1; SMN2PDK2 | |
| SCHEMBL3790092 | 0.80 | ALDH1A1 (0.44) | ERN1ALDH1A1HPGDSMN1; SMN2PDK2 | |
| SCHEMBL4037801 | 0.79 | LMNA (0.50) | ERN1ALDH1A1SMN1; SMN2CES2CES1 | |
| SCHEMBL31224923 | 0.79 | LMNA (0.50) | ERN1ALDH1A1SMN1; SMN2CES2CES1 | |
| SCHEMBL841590 | 0.79 | CES2 (0.42) | ALDH1A1HPGDCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11352330-B2 | Phenoxymethyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200339522-A1 | PHENOXYMETHYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| EP-3344619-B1 | PHENOXYMETHYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-10-28 | — | — | EP | disclosed |
| US-10640472-B2 | Phenoxymethyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20180201588-A1 | PHENOXYMETHYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-9802945-B2 | Imidazopyridazine derivatives as modulators of the GABAA receptor activity | PFIZER LIMITED (GB) | 2017-10-31 | — | — | US | disclosed |
| US-20170197965-A1 | Imidazopyridazine Derivatives As Modulators of the GABAA Receptor Activity | PFIZER LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| EP-3154979-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF THE GABAA RECEPTOR ACTIVITY. | Pfizer Limited (GB) | 2017-04-19 | — | — | EP | disclosed |
| EP-2702063-A1 | BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| US-8575160-B2 | Imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-11-05 | — | — | US | disclosed |
| US-8575160-B2 | Imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-11-05 | — | — | US | disclosed |
| US-8435976-B2 | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE (CH) | 2013-05-07 | — | — | US | disclosed |
| US-20130065893-A1 | IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-20130065893-A1 | IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-03-14 | — | — | US | disclosed |
| WO-2012148775-A1 | BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| EP-2475659-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011029802-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110059961-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339522-A1 | PHENOXYMETHYL DERIVATIVES | CNKSR1, RB1, RCOR1 | ERN1 1231/4885ALDH1A1 131/4885HPGD 2706/4885 |
| US-20130065893-A1 | IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP11B1, CYP21A2, CYP11B2 | ERN1 726/4885ALDH1A1 399/4885HPGD 236/4885 |
| US-10640472-B2 | Phenoxymethyl derivatives | CNKSR1, RB1, RCOR1 | ERN1 1231/4885ALDH1A1 131/4885HPGD 2706/4885 |
| US-20180201588-A1 | PHENOXYMETHYL DERIVATIVES | CNKSR1, RB1, RCOR1 | ERN1 1231/4885ALDH1A1 131/4885HPGD 2706/4885 |
| US-11352330-B2 | Phenoxymethyl derivatives | CNKSR1, RB1, RCOR1 | ERN1 1231/4885ALDH1A1 131/4885HPGD 2706/4885 |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | ERN1 2779/4885ALDH1A1 1110/4885HPGD 2111/4885 |
| US-20110059961-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | ERN1 844/4885ALDH1A1 1066/4885HPGD 854/4885 |
| US-20170197965-A1 | Imidazopyridazine Derivatives As Modulators of the GABAA Receptor Activity | GABRA5, GABRA3, GABRA2 | ERN1 4176/4885ALDH1A1 289/4885HPGD 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.